Viridian Therapeutics, Inc.\DE

Viridian Therapeutics, Inc.\DE

VRDN· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +62.3% in FY2025

Stephen Mahoney is the CEO of Viridian Therapeutics, Inc.\DE and was paid $6.8M in FY2025 (Dec), up 506%.

Pay$100 in the stock at the end of FY21 → $157
CEO pay is from each Viridian Therapeutics, Inc.\DE proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Stephen MahoneyFY2025
  2. 2Dr. Radhika TripuraneniFY2025
  3. 3Thomas BeethamFY2025
  4. 4Seth HarmonFY2025
  5. 5Jennifer TousignantFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Viridian Therapeutics, Inc.\DE paid its 5 named executives $19.6M in total in FY2025 (Dec). CEO Stephen Mahoney was paid $6.8M of that.

Name
Stephen MahoneyChief Executive Officer
Dr. Radhika TripuraneniNot disclosedNot disclosed
Thomas BeethamChief Operating Officer
Seth HarmonChief Financial Officer
Jennifer TousignantChief Legal Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers22

See all

The FY2024 (Dec) proxy of Viridian Therapeutics, Inc.\DE names 22 peer companies for pay. Pay versus performance data of Viridian Therapeutics, Inc.\DE for that year is not on file, so it has no rank.

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • Arlene M. MorrisDirector · 7 yr on the boardIndependentAudit, Compensation, Nominating—Paid as an executive
  • Jennifer K. MosesDirector · 4 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Viridian Therapeutics, Inc.\DE COO pay rose 365% to $3.8M. The stock rose 62% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Viridian Therapeutics, Inc.\DE CEO pay rose 506% to $6.8M. The stock rose 62% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Viridian Therapeutics, Inc.\DE CFO pay rose 243% to $2.6M. The stock rose 62% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Viridian Therapeutics, Inc.\DE General counsel pay fell 52% to $2.4M. The stock rose 62% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Viridian Therapeutics, Inc.\DE Division head pay fell 85% to $1.6M. The stock fell 12% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Viridian Therapeutics, Inc.\DE COO pay fell 83% to $809.5K. The stock fell 12% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Viridian Therapeutics, Inc.\DE CEO pay fell 91% to $1.1M. The stock fell 12% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Viridian Therapeutics, Inc.\DE CFO pay fell 88% to $770.7K. The stock fell 12% in FY2024 (Dec).
    DEF 14A
  9. Pay
    Viridian Therapeutics, Inc.\DE Former Chief Medical Officer pay fell 34% to $2.2M. The stock fell 12% in FY2024 (Dec).
    DEF 14A
  10. Pay
    Viridian Therapeutics, Inc.\DE Former Chief Medical Officer pay rose 55% to $3.3M. The stock fell 25% in FY2023 (Dec).
    DEF 14A
  11. Pay
    Viridian Therapeutics, Inc.\DE President pay fell 52% to $2.2M. The stock fell 25% in FY2023 (Dec).
    DEF 14A
  12. Board
    Sarah Gheuens joined the board of Viridian Therapeutics, Inc.\DE. Sarah Gheuens sits on no other public board.
    3

Filings6

See all
Proxy statementDEF 14AApr 17, 2026FY2025
Annual report10-KFeb 26, 2026FY2025
Proxy statementDEF 14AApr 25, 2025FY2024
Annual report10-KMar 3, 2025FY2024
Proxy statementDEF 14AApr 26, 2024FY2023
Annual report10-KFeb 27, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data